Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

QNRX vs VRAX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VRAX Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 4–4 Matrix Metrics)

VRAX Overall Winner 6-Pillar Tally: QNRX 0 – 3 VRAX (3 Tie) Matrix Metrics: QNRX 4 – 4 VRAX

As of Nov 20, 2026, Virax Biolabs Group Limited (VRAX) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). QNRX carries a Unified Composite Score of 46.1/100 (HOLD) at $3.28 (N/M Forward P/E, 0.0% operating margin), whereas VRAX carries 46.5/100 (HOLD) at $0.33 (N/M Forward P/E, -51515.2% operating margin).

  • Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile VRAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About QNRX vs VRAX
QNRX NASDAQ
Quoin Pharmaceuticals, Ltd. American Depositary Shares
Pharmaceutical Preparations
$3.28
-2.35% 1D
Market Cap $16.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.34β · 74% Vol
Unified Composite Score
46.1 / 100 HOLD
Tech 38.0 Fund 47.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.8%), weak momentum, RSI 32
RSI-14: 32.5 · SMA20: $3.81 · SMA50: $4.64
VRAX NASDAQ Head-to-Head Winner
Virax Biolabs Group Limited Ordinary Shares
In Vitro & In Vivo Diagnostic Substances
$0.33
-12.89% 1D
Market Cap $470,745
TTM Revenue $12,423
Forward P/E N/M
Beta / 30D Vol -8.20β · 162% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 45.0 Fund 50.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.8%), weak momentum, RSI 17
RSI-14: 17.3 · SMA20: $0.84 · SMA50: $1.56

6-Pillar Scorecard Institutional Category Breakdown (QNRX 0 – 3 VRAX)

Columns: Metric · QNRX · VRAX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E 7.6x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 37.9x
2. Growth & Scale VRAX
Revenue Growth (YoY) +0.0% +684.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $12,423
Market Cap $16.1M $470,745
3. Profitability & Quality VRAX
Gross Margin N/A 61.9%
Operating Margin 0.0% -51515.2%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -142.6% -78.6%
4. Balance Sheet & Cash Flow VRAX
Cash Generation (TTM) N/A -$6.0M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $5.97 Book/Sh · -142.6% ROE $13.08 Book/Sh · -78.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: QNRX (4) vs VRAX (4)
Institutional Metric QNRX VRAX Criterion Row Edge
Market Capitalization
Scale
$16.1M $470,745 Larger Scale QNRX
Trailing P/E Ratio
Valuation
7.6x N/M Lower Multiple QNRX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +684.9% Higher Growth VRAX
Operating Margin (TTM)
Profitability
0.0% -51515.2% Higher Margin QNRX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-142.6% -78.6% Higher ROE VRAX
52-Week Range Position
Momentum
0% ($3–$24) 2% ($0–$13) Stronger Trend VRAX
Beta / 30D Volatility
Risk Regime
1.34β · 74% Vol -8.20β · 162% Vol Lower Realized Risk QNRX
Unified Institutional Score
Composite Signal
46.1 / 100 (HOLD) 46.5 / 100 (HOLD) Higher Composite VRAX
Trailing 12M Revenue (USD)
Operating Scale
N/A $12,423 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 61.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 37.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($5.97 Book/Sh · -142.6% ROE) -$6.0M EBITDA ($13.08 Book/Sh · -78.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon QNRX +54.93 pp
QNRX: -18.2% · VRAX: -73.13%
3M Horizon QNRX +49.46 pp
QNRX: -39.48% · VRAX: -88.94%
6M Horizon VRAX +50.84 pp
QNRX: -31.24% · VRAX: +19.6%
1Y Horizon VRAX +57.34 pp
QNRX: -81.96% · VRAX: -24.62%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QNRX vs VRAX. Trailing 12-month operating profitability (QNRX 0.0% vs VRAX -51515.2%) and valuation multiples (QNRX N/M vs VRAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

QNRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-142.6% · N/M
VRAX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$12,423
Gross Margin61.9%
Op. Margin-51515.2%
ROE / Fwd P/E-78.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
QNRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact QNRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VRAX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VRAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
QNRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $16.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VRAX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $470,745 market capitalization and -51515.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ QNRX vs VRAX Key Questions & Quantitative Answers

As of Nov 20, 2026, Virax Biolabs Group Limited (VRAX) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). QNRX carries a Unified Composite Score of 46.1/100 (HOLD) at $3.28 (N/M Forward P/E, 0.0% operating margin), whereas VRAX carries 46.5/100 (HOLD) at $0.33 (N/M Forward P/E, -51515.2% operating margin). Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile VRAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VRAX leads the Growth & Scale pillar: QNRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VRAX at +684.9% YoY revenue growth and +0.0% YoY earnings growth on $12,423 TTM revenue (61.9% gross margin, -51515.2% operating margin). On trailing 12-month operating scale, QNRX generates N/A in USD-normalized revenue versus $12,423 for VRAX. In operating R&D and SG&A reinvestment, QNRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VRAX.

QNRX and VRAX trade at balanced relative valuation multiples. QNRX trades at N/M Forward P/E, 7.6x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas VRAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against QNRX (-142.6% ROE) versus VRAX (-78.6% ROE) capital efficiency.

In options market volatility and institutional positioning, QNRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 74% Vol realized risk). By comparison, VRAX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-8.20β · 162% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.